Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
To assess the efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes (T2D). This multicentre, double-blind, parallel-group study randomised Japanese patients with T2D insufficiently controlled with insulin (1:1:1) to empagliflozin 10 mg (n=89), empagliflozin 25 mg (n=90) or placebo (n=90) for 52 weeks. The primary endpoint was change in haemoglobin A1c (HbA1c) from baseline at 16 weeks. At 16 weeks, empagliflozin 10 mg and 25 mg significantly decreased HbA1c (adjusted mean difference, -0.92% [95% CI -1.11, -0.73] and -1.00% [-1.18, -0.82]; both p<0.0001) compared with placebo. This difference was maintained up to 52 weeks (adjusted mean difference at 52 weeks, -0.90% [-1.09, -0.70] and -0.96% [-1.15, -0.77]; both p<0.0001). At 52 weeks, significant improvements in fasting plasma glucose (adjusted mean difference, -27.62 mg/dL [-36.15, -19.08] and -31.99 mg/dL [-40.35, -23.62]) and body weight (-1.78 kg [-2.46, -1.10] and -1.92 kg [-2.58, -1.25]) were also seen with empagliflozin 10 mg and 25 mg compared with placebo (all p<0.0001). At 52 weeks, the frequency of adverse events (AEs) and serious AEs were similar between treatment groups; confirmed hypoglycaemia was reported slightly more in empagliflozin 10 mg and 25 mg patients (23.3% and 22.2% vs 14.4%). All hypoglycaemic events were mild in severity; no episodes required assistance. In Japanese patients with insufficiently controlled T2D, adding empagliflozin 10 mg or 25 mg to insulin treatment was associated with clinically meaningful reductions in HbA1c at 16 weeks and was generally well tolerated. This article is protected by copyright. All rights reserved.